Ecopia BioSciences Inc.'s Phase I Dose-Escalation Portion Successfully Completed
MONTREAL, QUEBEC -- (MARKET WIRE) -- January 11, 2007 -- Ecopia BioSciences Inc. (TSX: EIA) is pleased to announce the successful completion of the first portion, dose-escalation, of its Phase I clinical trial for ECO-4601, the Company's lead anticancer drug candidate. The completion of this milestone allows Ecopia to initiate the second portion of its clinical trial, the extension Phase.